



**Sydney Cancer Conference 2018**  
**11 - 12 October 2018**  
**International Convention Centre, Sydney**  
**Thursday 11 October 2018**



	Cockle Bay Room 1	Meeting Room C4.6	Meeting Room C4.7
<b>Session 1</b>	<b>Opening Ceremony and Plenary</b> Chairs: A/Prof Roger Bourne and Dr Jenny Wang		
09:00	Welcome to Country Craig Madden Opening Address <b>Prof David Currow</b> <i>Cancer Institute NSW</i>		
09:15	The last decade in cancer research - where we were then and where we are now <b>Prof Sanchia Aranda</b> <i>Cancer Council Australia</i>		
09:45	Changing role of imaging in neuro-oncology <b>Prof Susan Chang</b> <i>University of California, San Francisco</i>		
10:30	Morning Tea		
<b>Session 2</b>	<b>Clinical research</b> Chair: A/Prof Viive Howell	<b>Public health, quality of life and survivorship</b> Chair: Prof Elizabeth Sullivan	<b>Tumour microenvironment / stem cells</b> Chair: Dr Jenny Wang
11:00	Engaging rural clinicians in translational research: an exemplar in lung cancer <b>Dr Nicole Rankin</b> <i>Cancer Council NSW</i>	Cervical cancer elimination: When might it be achievable? <b>Prof Karen Canfell</b> <i>Cancer Council NSW</i>	Endothelial niche regulation of normal and malignant haematopoietic stem cells <b>Prof Ingrid Winkler</b> <i>Translational Research Institute</i>
11:30	62: Mechanisms of balance impairment in cancer survivors with chemotherapy-induced peripheral neuropathy <b>J. Matt McCrary</b>	46: Survivorship care plans and cancer survivors' patient-reported outcomes: A meta-analysis <b>Rebecca E. Hill</b>	115: Hepatic metastases from breast cancer: liver extracellular matrix controls growth, invasion and drug sensitivity <b>Anna Guller</b>
11:45	73: Investigating chemotherapy induced peripheral neuropathy in cancer survivors: an online patient survey <b>Eva Battaglini</b>	140: 'I was in a dark place and now I feel alive': Process evaluation of a psychological intervention for melanoma patients <b>Fay Huang</b>	98: ROBO2 is a stroma suppressor gene in the pancreas through regulation of TGF-beta <b>Andreia Pinho</b>
12:00	84: Moving towards an interactive cancer shared care plan solution <b>Mark Harris</b>	57: Future burden of cancer in Australia attributable to current modifiable behaviours <b>Maarit A. Laaksonen</b>	116: A novel cancer stem cell-targeted therapy characterised in highly translatable xenograft models of acute leukaemia <b>Basit Salik</b>
12:15	123: Optimising Dose via TDM: Mitotane as a Model for Implementation of Personalised Therapy <b>Stephen Ackland</b>	21: Public perceptions of thyroid cancer overdiagnosis, overtreatment and communication strategies: a qualitative study. <b>Caitlin Semsarian</b>	110: Delta40p53 is associated with stem cell markers in breast cancer <b>Kelly Avery-Kiejda</b>
12:30	7: Advanced cancer patient perspectives on consenting to molecular tumour profiling: A qualitative study <b>Nicole Bartley</b>	78: Cognitive Difficulties for Women after Breast Cancer: Compounding Problems When Trying to Return to Work <b>Joanne Lewis</b>	24: Understanding Fibroblast Activation Protein as a Molecular Target in Tumour Stroma Using Degradomics and Proteomics <b>Hui Emma Zhang</b>
12:35	66: The Needs of Young People After Death of a Family Member to Cancer: Validating the Bereaved Cancer Needs Inventory <b>Richard Tindle</b>	47: Salivary gland tumours and mobile phone use: fact or fiction? <b>Keshini Vijayan</b>	37: A new strategy to reduce prostate cancer stem cells by combining of BBI and α-TOS <b>Saki Kaneko</b>
12:40	Lunch and Poster Viewing		
<b>Session 3</b>	<b>Chairs: A/Prof Roger Bourne and Dr Jenny Wang</b>		
14:10	TNF in anti-tumour immunity and resistance to immunotherapy <b>Dr Jane Oliaro</b> <i>Peter MacCallum Cancer Centre</i>		
14:55	The survivorship experiences of Australian Aboriginal and Torres Strait Islander peoples with cancer <b>A/Prof Patricia Valery</b> <i>QIMR Berghofer</i>		
15:40	Cancer Survivor <b>Ms Cheryl Grant</b>		
16:00	Overview of translational research workshop agenda		
16:10	Afternoon Tea		
<b>Session 4</b>	<b>Translational Cancer Research Workshop</b> Chair: A/Prof Kieran Scott		
16:40	Big Data: "How will all these data help the cancer patient?" Workshop Panel Moderator: Mr Dan Gaffney, <i>The University of Sydney</i> <b>Panelists</b> - Ms Cheryl Grant, <i>Consumer presenter</i> - Ms Nadia Levin, <i>Research Australia</i> - Prof Tim Shaw, <i>The University of Sydney</i> - A/Prof Kristine Barlow-Stewart, <i>The University of Sydney</i> - A/Prof Winston Liauw, <i>South Eastern Sydney Local Health District</i>		
18:00 - 19:00	Conference Social Event and Poster Viewing		

\*Please note the program is current as of 10 October and subject to change

**Friday, 12 October 2018**

	Cockle Bay Room 1	Meeting Room C4.6	
<b>Session 5</b>		<b>Early Career Researcher &amp; Postgraduate Student Breakfast Session</b> Chair: Prof. Elizabeth Sullivan	
08:00		<p>"Research as a career in the 21st century"</p> <p><b>Panelists</b> Chair - Prof. Elizabeth Sullivan</p> <ul style="list-style-type: none"> <li>- Prof. Susan Chang, <i>University of California, San Francisco</i></li> <li>- A/Prof Kellie Charles, <i>A/Prof in Pharmacology, School of Medical Sciences, University of Sydney</i></li> <li>- Prof Roger Reddel, <i>Kids Cancer Alliance (Director, Children's Medical Research Institute)</i></li> <li>- Stephen Clarke, <i>University of Sydney</i></li> </ul> <p><b>Invited Guests</b></p> <ul style="list-style-type: none"> <li>- Prof. Michael Boyer, <i>Sydney Catalyst</i></li> <li>- Prof. Paul Harnett, <i>Sydney West</i></li> <li>- Prof. Alexander Engel, <i>Sydney Vital</i></li> <li>- Prof. Jennifer Byrne, <i>Kids Cancer Alliance</i></li> <li>- Prof. Mark Harris, <i>TCRN</i></li> <li>- Prof. Paul De Souza, <i>CONCERT</i></li> <li>- Prof. Stephen Ackland, <i>Hunter Cancer Research Alliance</i></li> </ul> <p>Tickets available at additional cost</p>	
<b>Session 6</b>	<b>Overview of CINSW Translational Cancer Research Centres</b> Chairs: Dr Kimberly Docking and A/Prof Therese Becker		
09:00	Prof Paul De Souza, Prof Mark Harris, Prof Alexander Engel, Prof Michael Boyer, Prof Paul Harnett, A/Prof Tracy Brian, Prof Stephen Ackland		
09:45	Precision systems oncology: from leukemias to solid tumors Prof Olli P Kallioniemi <i>Karolinska Institute, Sweden and Institute for Molecular Medicine Finland, University of Helsinki</i> Chair: Dr Kimberly Docking		
	Cockle Bay Room 1	Meeting Room C4.6	Meeting Room C4.7
10:30	<b>Morning Tea</b>		
<b>Session 7</b>	<b>Cancer biology</b> Chair: Dr Esther Lim	<b>Clinical biomarkers</b> Chair: Jessica Lee	<b>Genomics, prevention &amp; screening</b> Chair: A/Prof Viive Howell
11:00	Steps towards a comprehensive survey of the proteomic landscape of human cancer Prof Roger Reddel <i>The University of Sydney</i>	Blood based biomarkers for prognosis and monitoring of patients with melanoma Dr Elin Gray <i>Edith Cowan University</i>	How many cancers might we prevent? Analyses of the preventable burden of cancer in Australia? Prof David Whiteman <i>QIMR Berghofer</i>
11:30	19: Dietary sucrose intake increases liver tumour burden in a mouse model of diethylnitrosamine-induced liver cancer Daniel Vitale	97: Nuclear IGFBP-3 is a potential biomarker for response to EGFR-sphingosine kinase targeted therapy in TNBC Janet Martin	145: Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia Mawar Karsa
11:45	88: Targeting NAD+ biosynthesis as a therapeutic strategy for high-risk paediatric ALL Klaartje Somers	79: CD83 is a New Potential Biomarker and Therapeutic Target for Lymphoma Xinsheng Ju	109: Amiloride Provides Neuroprotection Against Preclinical Paclitaxel-Induced Peripheral Neuropathy Justin Lees
12:00	101: Targeting the aryl-hydrocarbon receptor (AhR) pathway to selectively kill breast cancer cells Jennette Sakoff	68: Sensitivity testing of CTCs to chemotherapeutic agents as a predictor of therapeutic response and clinical outcome Joachim Fluhrer	102: Can risk attitudes determine sun-exposure behaviours and modify a melanoma genomic risk intervention? Rachael Morton
12:15	108: Targeting a novel metabolic regulatory mechanism in acute myeloid leukaemia. Patrick Connerty	12: Polygenic breast cancer risk: A prospective study of uptake and outcomes among high-risk women Tatiane Yanes	6: The mammographic density of Indigenous women attending breast screening in the Northern Territory Kriscia Tapia
12:30	126: Targeting ABCE1 disables MYC-driven protein synthesis to block neuroblastoma progression Jixuan Gao	16: TMEM and Menacalc: new prognostic markers for breast cancer Thomas Rohan	61: A genetic variant in telomerase gene modifies cancer risk in Lynch syndrome patients harbouring MSH2 mutations Bente Talseth-Palmer
12:35	72: Targeting adaptive metabolic reprogramming in pancreatic ductal adenocarcinoma to overcome chemotherapy resistance Sarah Hancock	45: Lymphoma in Border Collies: Survey results and genetic investigations Pamela Soh	23: Germline genomic analysis in childhood cancer patients suspected of genetic predisposition to cancer Dianne E. Sylvester
12:40	<b>Lunch and Poster viewing</b>		
<b>Session 8</b>	<b>Cancer Immunology</b> Chairs: Ms Sherry Tu and Mr Abel Tan	<b>Emerging Technologies</b> Chair: Dr Nikki Verrills	<b>Imaging &amp; radiotherapy/ Bioinformatics</b> Chair: A/Prof Roger Bourne
14:00	Emerging Advances in Cellular Therapies: Immune correlates to immune contexture Prof Rajiv Khanna <i>QIMR Berghofer</i>	Light and nanotechnology for probing and interacting with biological systems Prof Ewa Goldys <i>UNSW Australia</i>	Targeted Radiotherapy: Current Trends and Future Directions Prof Paul Keall <i>The University of Sydney</i>
14:30	111: Circulating cytokines predict toxicity in melanoma patients receiving combination immunotherapy. Esther Lim	13: A modular strategy for the bioconjugation of nanoparticles in targeted cancer theranostics Andrew Care	36: Heterogeneity in the single-cell signalling response promotes chemoresistance in neuroblastoma David Croucher
14:45	39: Microglial responses to syngeneic glioblastoma in a 18-KDA translocator protein (TSPO) knockout Manuel Graeber	80: Three-dimensional brain tumour models: a tool to advance the detection and treatment of Glioblastoma Multiforme Annemarie Nadort	9: Controlled drug release from a liposomal delivery platform triggered by X-ray radiation Wei Deng
15:00	33: Transient 'priming' by FAK inhibition improves sensitivity to standard-of-care in Pancreatic Ductal Adenocarcinoma Kendelle Murphy	26: CADg: a novel mammographic computer-aided detection tool incorporating the gist of the abnormal Ziba Gandomkar	146: The advantage of phase-contrast imaging in computed tomography of the breast Seyedamir Tavakoli Taba
15:15	92: Overcoming Pgp-Mediated Drug-Resistance by Releasing Lysosomal Stored Doxorubicin with Lysosomal Targeting Agents Lionel Leck	11: Cracking the code of intra-tumour heterogeneity during carcinoma response to therapy using single cell technology Naisana Seyedasi	91: Discovery of novel prognostic markers in triple-negative breast cancer by MALDI MS imaging Robert Baxter
15:30	104: Expression of lncRNAs in ovarian cancer-associated fibroblasts is prognostic for patient survival Emily Colvin	22: Australia's pilot trial of digital breast tomosynthesis (3Dmammography) population-based screening: Interim results Nehmat Houssami	127: Fifty shades of radiobiology: alpha/beta ratios exposed Ana Esteves
15:35	70: Dual inhibition of JAK and Src: A novel and promising therapeutic combination for pancreatic cancer Ashleigh Parkin	133: Liquid biopsies to detect clinical breast cancer biomarkers Sarah Jeffreys	103: False positive results and incidental findings with CT or PET/CT surveillance in stage III melanoma patients Rachael Morton
15:40	<b>Afternoon Tea</b>		
16:00	Closing remarks and awards presentation Chairs: Dr Jenny Wang and A/Prof Roger Bourne		